Gara Jalqabaatti › Kansara Qara'a Non-Small Cell › Texas › Fort Worth
Qorannoo klinikaalii Kansara Qara'a Non-Small Cell Fort Worth, TX keessatti
Qorannoo 18 Kansara Qara'a Non-Small Cell f Fort Worth fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- START Center for Clinical Research, Fort Worth
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Namoota walitti qabaa jiraSadarkaa 3
- The Center For Cancer And Blood Disorders, Fort Worth
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 2
- START Fort Worth, Fort Worth
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Namoota walitti qabaa jiraSadarkaa 3
- Texas Oncology - DFW, Fort Worth
- The Center for Cancer and Blood Disorders, Fort Worth
- The Center for Cancer and Blood Disorders, Burleson · Miili 13 fagaatti
- fi 1 dabalataa
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Texas Oncology - DFW, Fort Worth
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- The Center for Cancer and Blood Disorders, Fort Worth
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Fort Worth
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Fort Worth
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Namoota walitti qabaa jiraSadarkaa 3
- Clinical Study Site, Fort Worth
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Namoota walitti qabaa jiraSadarkaa 1/2
- Start Dfw, Fort Worth
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- JPS Health Network, Fort Worth
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Namoota walitti qabaa jiraSadarkaa 1
- Texas Oncology - DFW, Fort Worth
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Namoota walitti qabaa jiraSadarkaa 1/2
- USOR Texas Oncology, Fort Worth
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- UT Southwestern - Simmons Cancer Center - Fort Worth, Fort Worth
ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Start Ccbd, Llc, Fort Worth
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Namoota walitti qabaa jiraSadarkaa 1
- START Dallas Fort Worth, LLC, Fort Worth
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- START Dallas Fort Worth, LLC, Fort Worth
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- START Dallas, Fort Worth
Qorannoo Kansara Qara'a Non-Small Cell magaalota biroo keessatti
- Houston, TXQorannoo 145
- New York City, NYQorannoo 120
- Arlington, VAQorannoo 104
- Nashville, TNQorannoo 97
- Boston, MAQorannoo 90
- Los Angeles, CAQorannoo 87
- St. Louis, MOQorannoo 73
- Chicago, ILQorannoo 61
- Baltimore, MDQorannoo 60
- San Antonio, TXQorannoo 59
- Columbus, OHQorannoo 56
- Washington, DCQorannoo 55
Qorannoo biroo Fort Worth keessatti
- Kansarii OvariiQorannoo 17
- Kansa EndometiriyaaliiQorannoo 12
- Saree OljooQorannoo 11
- Saree (Gosoota Hunda)Qorannoo 9
- Kansarii ProstateQorannoo 9
- Cufama OnneeQorannoo 7
- Kansarii ColorectalQorannoo 7
- Kansaar Onnee Triple-NegativeQorannoo 7
- Kansara MetastatikiiQorannoo 7
- Kansara Harkaa (Karsinomaa Seli Renal)Qorannoo 7
- Colitis UlcerativeQorannoo 7
- Degenereshinii MakulaariiQorannoo 7
Kanneen ClinicalTrials.gov irraa argaman, daataa 05-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.